However, treatment with the GPER agonist (G-1) counteracted these changes, rising the cardiac SOD activity (OVX+T2D+G-1 vs. OVX+T2D+Veh, P ≤ 0.05, Fig 5C). Here, GPER1 is linked to type 2 diabetes mellitus.